European Radiology:CT灌注预测的梗死核心与急性卒中临床结果之间的关系

2022-04-19 shaosai MedSci原创

研究表明,CTP衍生的pIC可能会大幅高估缺血性改变,在早期完全再灌注的情况下尤为显著。

评估梗死的非活性组织或梗死核心是评估急性卒中患者病情重要的基线影像标志之一。梗死核心可以通过几种不同的技术来估计,如平扫CT中的ASPECTS、CT灌注(CTP)中脑血容量或脑血流(CBF)以及磁共振成像中散加权成像。

由于CTP的临床可用性较高,该技术被广泛用于急性卒中以获得预测的梗死核心(pIC)体积。尽管pIC与临床结果指标之间存在整体关联,但一些治疗前和治疗相关的变量可以改变这些关系,包括年龄、基线国家卫生研究院卒中量表(NIHSS)、ASPECTS、CTP获取时间、再灌注程度、旁路或高血糖状态。具体来说,CTP衍生的pIC可能会大幅高估缺血性改变,在早期完全再灌注的情况下尤为显著。因此,更好地界定这些变量之间的相互作用,对保证在早期卒中中的更好的结果预测意义重大

近日,发表在European Radiology杂志的一项研究在假设pIC的预后准确性可被一些基线和治疗相关的变量所改变的情况下,一个有大血管前循环闭塞急性缺血性卒中患者队列对所有患者在卒中发生后8小时内进行CTP成像,以明确pIC和临床预后之间最相关的改变因素

本研究纳入了828名患有急性颈动脉近段闭塞患者,这些患者在卒中发生后8小时内接受了全脑CTP成像。在CTP地图上计算pIC(脑血流<30%),不良的临床结果被定义为90天改良的Rankin评分>2。通过对派生队列(n = 654)的一阶和高级互动分析,评估pIC和临床结果之间的潜在中介因素以获得预测模型。在一个独立的队列(n = 174)中进一步验证了衍生的模型。 

pIC的体积与不良的临床结果不良显著相关(OR = 2.19,95% CI = 1.73 - 2.78,P < 0.001)。这种关联的强度取决于基线国家卫生研究院卒中量表、葡萄糖水平、使用血栓切除术以及年龄与血栓切除术的相互作用。在推导队列和验证队列中,结合这些变量的模型对预测临床结果显示出良好的分辨力(受试者工作特性曲线下面积分别为0.780(95%CI=0.746-0.815)和0.782(95%CI=0.715-0.850))。  


 应用该模型的代表性示例(A),不同程度的暴露于所确定标志物的汇总表(B)。CBF:脑血流;DT:延迟时间;mRS:改良的Rankin量表评分;MT:机械血栓切除术;NIHSS:美国国立卫生研究院卒中量表;pIC:预测梗死核心

本研究提示CTP衍生的pIC在预测急性缺血性卒中患者部分亚组临床结果方面的准确性有限,这些亚组是在卒中发生后8小时内成像、并由特定的基线或治疗变量定义。同时,增加某些简单的基线临床变量会提高由pIC估计得出的结果预测的准确性。因此,研究结果表明,在评估pIC的预后价值时,必须同时考虑这些变量对结果影响

原文出处

Carlos Laredo,Aleix Solanes,Arturo Renú,et al.Clinical and therapeutic variables may influence the association between infarct core predicted by CT perfusion and clinical outcome in acute stroke.DOI:10.1007/s00330-022-08590-0

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898892, encodeId=1fdc189889212, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Oct 22 01:33:22 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729508, encodeId=cf251e295083c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Nov 25 21:33:22 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212879, encodeId=cd5512128e9ea, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Wed Apr 20 15:55:37 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212455, encodeId=b422121245544, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Tue Apr 19 10:48:19 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284481, encodeId=969d1284481e1, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Mon Apr 18 00:33:22 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898892, encodeId=1fdc189889212, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Oct 22 01:33:22 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729508, encodeId=cf251e295083c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Nov 25 21:33:22 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212879, encodeId=cd5512128e9ea, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Wed Apr 20 15:55:37 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212455, encodeId=b422121245544, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Tue Apr 19 10:48:19 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284481, encodeId=969d1284481e1, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Mon Apr 18 00:33:22 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-11-25 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898892, encodeId=1fdc189889212, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Oct 22 01:33:22 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729508, encodeId=cf251e295083c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Nov 25 21:33:22 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212879, encodeId=cd5512128e9ea, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Wed Apr 20 15:55:37 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212455, encodeId=b422121245544, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Tue Apr 19 10:48:19 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284481, encodeId=969d1284481e1, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Mon Apr 18 00:33:22 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-20 清漩

    #学习#学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1898892, encodeId=1fdc189889212, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Oct 22 01:33:22 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729508, encodeId=cf251e295083c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Nov 25 21:33:22 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212879, encodeId=cd5512128e9ea, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Wed Apr 20 15:55:37 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212455, encodeId=b422121245544, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Tue Apr 19 10:48:19 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284481, encodeId=969d1284481e1, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Mon Apr 18 00:33:22 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-19 清漩

    #学习#学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1898892, encodeId=1fdc189889212, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Oct 22 01:33:22 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729508, encodeId=cf251e295083c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Nov 25 21:33:22 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212879, encodeId=cd5512128e9ea, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Wed Apr 20 15:55:37 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212455, encodeId=b422121245544, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Tue Apr 19 10:48:19 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284481, encodeId=969d1284481e1, content=<a href='/topic/show?id=d2155222281' target=_blank style='color:#2F92EE;'>#急性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52222, encryptionId=d2155222281, topicName=急性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Mon Apr 18 00:33:22 CST 2022, time=2022-04-18, status=1, ipAttribution=)]

相关资讯

JAHA:急性卒中和房颤患者早期节律控制的风险和益处

急性缺血性卒中患者早期节律控制策略在12个月内减少了持续性AF和复发性卒中,而复合不良结局没有增加。

Stroke:脑电图可能改善急性卒中和大血管闭塞的诊断

将脑电图数据添加到临床指标中可改善对急性卒中/TIA以及LVO急性卒中的诊断。在急诊科中快速采集干电极脑电图是可行的,值得用于院前评估。

Stroke:既往抗血小板治疗对急性卒中患者血管内治疗后结局的影响

既往APT不影响血管内治疗后的血管造影和功能结局,因此,不应考虑急性血运重建策略。

Stroke:脑淀粉样血管病的急性卒中患者血管内治疗效果分析

血管内血栓切除术联合或不联合溶栓对伴有CAA的急性缺血性卒中患者都有益,但与较差的功能结局相关。

European Radiology:这一影像学指标,成为了急性卒中出现恶性脑水肿的新兴预测手段!

Alberta卒中项目早期CT评分(ASPECTS)是一个半定量的评分系统,可评估CT图像上的梗死程度、缺血性改变的程度以及大脑中动脉(MCA)区域内的局灶性肿胀。

Stroke:急性卒中后的长期生存率、卒中复发和预期寿命

在这个人群范围的研究中,急性卒中后的死亡和复发很常见,并且急性卒中与预期寿命的大幅减少有关。为了降低这些风险,需要进一步改进卒中的治疗和二级预防。